logo
welcome
Sky News

Sky News

Alzheimer's drug lecanemab that slows decline given green light in UK - but won't be available on NHS

Sky News
Summary
Nutrition label

72% Informative

Lecanemab can slow the decline in memory and mental agility by 27% in patients with mild Alzheimer's.

But a separate NHS watchdog has ruled it's not cost-effective and won't be available.

Decision means the first drug to show an effect in Alzheimer's will only be available privately.

In the US the treatment costs 20,000 a year.

VR Score

77

Informative language

81

Neutral language

25

Article tone

semi-formal

Language

English

Language complexity

59

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links